2026 is a transitional year; profitability waits until 2028
Fourlis Holdings, the Greek retail conglomerate, has posted 12% sales growth — a number that tells only part of the story. Beneath the headline lies a company in deliberate metamorphosis, trading near-term profitability for long-term structural strength through digital investment and pharmacy expansion. The gains are real, particularly in sporting goods, but the rewards of transformation are penciled in for 2028 and 2029, asking shareholders to hold faith across an uncertain economic horizon.
- INTERSPORT's 11.5% growth to €202M and a 22% surge across sporting goods signal genuine consumer demand, not just shelf-space expansion — like-for-like sales near 9% confirm customers are spending more, not just showing up.
- A cyber incident and Nike's ERP system overhaul forced excess inventory buildup, tying up cash in warehouses and creating operational drag that management hopes to unwind before year's end.
- The company is pushing Holland & Barrett into all Doctor Pharmacy locations, betting that health and wellness retail offers more stable margins than the volatile sporting goods channel.
- Digital transformation investments won't yield meaningful productivity gains until mid-2027 at the earliest, with EBITDA recovery of just 0.5–1% annually targeted through 2028–2029 — a long wait in a turbulent economy.
- First-quarter 2026 sales are running 13% ahead year-to-date, but management is withholding forward guidance entirely, citing macroeconomic volatility and choosing flexibility over forecasts.
Fourlis Holdings reported 12% full-year sales growth, a solid headline that conceals a more complicated reality. The sporting goods division is carrying the momentum: INTERSPORT grew 11.5% to just over €202 million, Foot Locker contributed €19.2 million, and the segment as a whole jumped 22%. Crucially, like-for-like growth near 9% suggests the gains reflect genuine consumer engagement, not just new store openings.
Yet the company is openly framing 2026 as a transitional year — corporate shorthand for a period of investment pain before structural gain. A digital transformation is underway that won't begin delivering productivity improvements until mid-2027, and management is targeting EBITDA recovery of only 0.5% to 1% annually, putting meaningful profitability improvement as far out as 2028 or 2029.
Near-term pressures compound the picture. A cyber incident prompted precautionary inventory buildup, and Nike's enterprise system transition required additional stock preparation — cash that is currently sitting in warehouses rather than working for the business. The company expects to normalize these levels by year's end.
On the expansion front, Fourlis is aggressively integrating Holland & Barrett into its Doctor Pharmacy network, a strategic bet that health and wellness retail offers more resilient margins than sporting goods alone. First-quarter 2026 sales are running 13% ahead, but management declined to issue specific guidance, citing macroeconomic uncertainty and opting instead for disciplined flexibility. The sales story is encouraging; the profitability story is still being written.
Fourlis Holdings is navigating a delicate balancing act. The Greek retail conglomerate reported a 12% increase in sales for the full year, a solid result that masks a more complicated picture underneath—one where growth is real but profitability remains elusive, and where the company is betting heavily on transformation that won't pay off for another two or three years.
The sporting goods division is where the momentum lives. INTERSPORT, the company's flagship athletic retailer, grew 11.5% to reach just over 202 million euros, while Foot Locker added another 19.2 million euros to the mix. Together, the sporting goods segment jumped 22%, a number that speaks to underlying brand strength even as the broader retail environment remains choppy. INTERSPORT's like-for-like growth—the measure that strips out new store openings and focuses on what existing locations are actually selling—came in near 9%, suggesting the gains aren't just coming from expansion but from customers actually spending more.
Yet 2026 is being framed internally as a transitional year, a term that in corporate speak usually means things are going to get worse before they get better. The company is in the thick of a digital transformation that won't begin delivering meaningful productivity gains until mid-2027 at the earliest. Management is targeting EBITDA recovery of between 0.5% and 1% annually, which would bring the company close to its original targets by 2028 or 2029. That's a two-to-three-year wait for profitability to meaningfully improve, a long runway in an uncertain economy.
Some of the current strain comes from practical, near-term challenges. A cyber incident forced the company to build up inventory as a buffer against supply chain disruption, and Nike's transition to a new enterprise resource planning system required additional stock preparation. The company says it plans to work down these excess inventory levels by year's end, which should help free up cash that's currently tied up in warehouses and distribution centers.
There's also an aggressive expansion underway in pharmacy retail. Fourlis is pushing Holland & Barrett, a health and wellness brand, into all of its Doctor Pharmacy locations. Doctor Pharmacy itself is aiming to build out a large network aggressively, and Holland & Barrett will be a key part of that growth strategy. It's a bet that the pharmacy channel offers better margins and more stable demand than pure sporting goods retail.
The year has started stronger than expected. Sales through the first quarter were up 13% year-to-date, which is ahead of the full-year 12% result. But management is being cautious about what that means. The company declined to provide specific forward guidance, citing market volatility and macroeconomic uncertainty. Instead, executives emphasized disciplined execution and maintaining flexibility—corporate language for: we're going to move carefully and adjust as conditions change.
What emerges from this picture is a company in transition, with real sales momentum but real profitability headwinds, betting that its digital infrastructure investments and pharmacy expansion will eventually unlock the margins it needs. For now, investors are being asked to wait.
Citações Notáveis
The transformation journey is expected to yield significant productivity gains from systems by mid-2027 and onwards— Fourlis Holdings management
While 2026 is a transitional year, we aim to recover 0.5% to 1% per year in EBITDA, reaching close to our target by 2028-2029— Fourlis Holdings management
A Conversa do Hearth Outra perspectiva sobre a história
Why is 2026 being called a transitional year if sales are growing at 12%?
Because sales growth and profit growth are different things. The company is investing heavily in new systems and infrastructure right now, which costs money. Those investments won't pay off in terms of actual profit until 2027 or later.
So the inventory buildup—that's temporary?
Yes. The cyber incident and Nike's system change forced them to hold extra stock as a safety measure. They're planning to sell through that excess by the end of the year, which will improve cash flow.
What about the pharmacy expansion? Is that a sign they're losing confidence in sporting goods?
Not necessarily losing confidence—INTERSPORT is still growing well. But pharmacy retail tends to have steadier demand and better margins. It's diversification, not abandonment.
Why no specific guidance for 2026?
Macroeconomic volatility. They don't want to promise something they can't deliver if conditions shift. The year started strong at 13% sales growth, but they're being cautious about what that means for the full year.
When should investors actually expect profitability to recover?
2028 or 2029, if the digital transformation delivers as planned. That's a long wait, which is why management is emphasizing disciplined execution and flexibility.